This inventor holds 2 USPTO granted patents. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, Medigene Ag. Active years: 2013-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 168 
2 out of 48 
Years Active: 2013-2016
Title: Heiner Schaefer: Innovator in Tumor Treatment
Introduction
Heiner Schaefer is a notable inventor based in Kiel, Germany. He has made significant contributions to the field of tumor treatment through his innovative research and development. With a total of 2 patents, Schaefer has focused on advancing medical technologies that target cancer effectively.
Latest Patents
Schaefer's latest patents include the treatment of tumors using a specific anti-L1 antibody. The present invention relates to the anti-L1 monoclonal antibody 9.3, as well as to related antibodies or binding molecules. This invention emphasizes the uses of these antibodies, particularly in tumor treatment, showcasing Schaefer's commitment to improving cancer therapies.
Career Highlights
Throughout his career, Heiner Schaefer has worked with prominent organizations such as Medigene AG and the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Schaefer's notable coworkers include Daniela Kelm and Peter Altevogt. Their collaborative efforts have further enhanced the impact of Schaefer's inventions in the medical community.
Conclusion
Heiner Schaefer's innovative work in tumor treatment exemplifies the importance of research and development in combating cancer. His contributions through patents and collaborations continue to influence the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile